Abstract
China faces a significant burden of epilepsy, with approximately 6 million active cases annually, 60% of which involve partial-onset seizures. Perampanel (PER), a novel anti-epileptic drug, was recently included in the Chinese National Reimbursement Drug List (NRDL). This study evaluates the cost-effectiveness and budget impact of PER compared to lacosamide (LCM) from a health system perspective. Using a Markov model to simulate lifetime transitions between health states, the study found that PER (8 mg/day and 4 mg/day) is a "dominant" strategy—offering higher quality-adjusted life years (QALYs) at lower costs. Budget impact analysis suggests that while PER increases the total insurance budget, it significantly expands patient coverage.
Introduction
Epilepsy is a major public health challenge in China. For the millions of patients with partial-onset seizures, finding effective adjunctive therapies is crucial. While new treatments like Perampanel (PER) and Lacosamide (LCM) are available, their long-term economic value within the Chinese healthcare system requires assessment. Since PER's inclusion in the NRDL in 2020, evidence regarding its cost-effectiveness has been limited. This research provides a comprehensive economic evaluation to guide clinical and policy decisions.
Methods
The researchers developed a Markov model to simulate the lifelong progression of epilepsy in Chinese patients. The model follows patients until 99.9% mortality, with transitions occurring between health states defined by seizure frequency (ranging from "seizure-free" to ">=52 seizures per year").
The analysis compared two dosage levels: PER 8 mg/day vs. LCM 400 mg/day, and PER 4 mg/day vs. LCM 200 mg/day. Data sources included clinical trials (NCT01618695 and NCT01710657) for efficacy, the China Drug Bidding Database for costs, and WHO life tables for mortality. Costs and health outcomes were discounted at an annual rate of 5%.
Results
Cost-Effectiveness Analysis
The study found that PER is a "dominant" therapeutic option, meaning it is both more effective and less expensive than LCM.
- 8 mg/day comparison: PER increased QALYs by 0.054 and saved $2,390 per patient compared to LCM 400 mg/day.
- 4 mg/day comparison: PER increased QALYs by 0.010 and saved $860 per patient compared to LCM 200 mg/day.
Deterministic sensitivity analysis revealed that utility values and discount rates were the factors with the greatest impact on the incremental cost-effectiveness ratio, though the results remained robust across scenarios.
Budget Impact Analysis
The inclusion of PER in the NRDL is projected to require an incremental budget of $1.28 million in 2021**, rising to **$4.56 million by 2023. However, this investment facilitates coverage for significantly more patients—reaching an estimated 8,983 eligible individuals by the third year.
Discussion and Conclusion
A key driver of PER’s value is its superior ability to achieve a "seizure-free" state in the Chinese population compared to LCM. Reducing seizure frequency not only improves quality of life but also lowers long-term medical service costs.
While the study relies on some foreign data proxies for utility and mortality due to a lack of local longitudinal data, the findings strongly support the high value of PER as an add-on therapy in China. In conclusion, PER (8 or 4 mg/day) offers a dominant cost-effectiveness advantage over LCM with an acceptable budget impact, making it a high-value choice for the Chinese healthcare system.
Summary updated